Equasens Société anonyme Logo

Equasens Société anonyme

0R9T.L

(2.0)
Stock Price

42,85 EUR

17.84% ROA

22.73% ROE

16.98x PER

Market Cap.

790.639.489,00 EUR

28.21% DER

2.38% Yield

21.41% NPM

Equasens Société anonyme Stock Analysis

Equasens Société anonyme Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Equasens Société anonyme Fundamental Stock Analysis
# Analysis Rating
1 Revenue Growth

With a track record of consistent revenue growth in the past five years, this company presents a compelling opportunity.

2 Net Profit Growth

The net profit of this company has steadily increased over the last five years, showcasing a favorable financial performance and making it an enticing option for investors seeking growth potential.

3 ROE

ROE surpassing expectations (102.66%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect.

4 Dividend Growth

With a history of consistent dividend increases over the last three years, the company has proven to be a reliable choice for investors seeking reliable income.

5 Buffet Intrinsic Value

The company's stock presents an enticing opportunity as it appears undervalued (280) by Warren Buffett's formula, indicating that its intrinsic value exceeds the market price.

6 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

7 Graham Number

Based on the Graham number, this company's stock price appears to be higher than its intrinsic value, signaling a potentially unfavorable investment choice.

8 Dividend

Investors should note the absence of dividends from the company in the last three years, indicating potential financial challenges.

9 ROA

The stock's ROA (-31.76%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

10 PBV

The stock's high Price-to-Book Value (P/BV) ratio (18.1x) suggests it's overvalued, potentially making it an expensive investment.

11 DER

The company has a high debt to equity ratio (131%), which means it owes a lot of money compared to what it actually owns, making it financially risky.

Equasens Société anonyme Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Equasens Société anonyme Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

Equasens Société anonyme Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Equasens Société anonyme Revenue
Year Revenue Growth
2004 60.669.000
2005 63.616.000 4.63%
2006 67.357.000 5.55%
2007 70.949.000 5.06%
2008 74.800.000 5.15%
2009 81.621.000 8.36%
2010 91.551.000 10.85%
2011 97.064.000 5.68%
2012 108.722.000 10.72%
2013 113.407.000 4.13%
2014 114.560.000 1.01%
2015 113.477.000 -0.95%
2016 128.381.000 11.61%
2017 129.669.000 0.99%
2018 148.480.000 12.67%
2019 158.569.000 6.36%
2020 171.754.000 7.68%
2021 193.069.000 11.04%
2022 207.144 -93105.21%
2022 214.075.000 99.9%
2023 428.672.000 50.06%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Equasens Société anonyme Research and Development Expenses
Year Research and Development Expenses Growth
2004 0
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 3.668.000 100%
2016 3.715.000 1.27%
2017 648.000 -473.3%
2018 0 0%
2019 0 0%
2020 3.471.000 100%
2021 0 0%
2022 6.420 100%
2022 6.551.000 99.9%
2023 6.184.000 -5.93%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Equasens Société anonyme General and Administrative Expenses
Year General and Administrative Expenses Growth
2004 0
2005 0 0%
2006 0 0%
2007 27.754.000 100%
2008 28.555.000 2.81%
2009 31.433.000 9.16%
2010 46.150.000 31.89%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2022 0 0%
2023 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Equasens Société anonyme EBITDA
Year EBITDA Growth
2004 9.324.000
2005 11.269.000 17.26%
2006 12.282.000 8.25%
2007 -10.418.000 217.89%
2008 -2.261.000 -360.77%
2009 16.885.000 113.39%
2010 19.083.000 11.52%
2011 19.742.000 3.34%
2012 22.584.000 12.58%
2013 25.943.000 12.95%
2014 28.003.000 7.36%
2015 31.171.000 10.16%
2016 34.854.000 10.57%
2017 38.497.000 9.46%
2018 44.221.000 12.94%
2019 50.694.000 12.77%
2020 55.683.000 8.96%
2021 64.351.000 13.47%
2022 54.200 -118628.78%
2022 69.013.000 99.92%
2023 140.316.000 50.82%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Equasens Société anonyme Gross Profit
Year Gross Profit Growth
2004 34.442.000
2005 38.167.000 9.76%
2006 40.149.000 4.94%
2007 70.949.000 43.41%
2008 57.133.000 -24.18%
2009 49.818.000 -14.68%
2010 66.073.000 24.6%
2011 69.224.000 4.55%
2012 64.566.000 -7.21%
2013 27.704.000 -133.06%
2014 30.208.000 8.29%
2015 33.267.000 9.2%
2016 37.649.000 11.64%
2017 41.572.000 9.44%
2018 47.216.000 11.95%
2019 108.247.000 56.38%
2020 119.305.000 9.27%
2021 133.816.000 10.84%
2022 66.652 -200668.17%
2022 145.522.000 99.95%
2023 112.516.000 -29.33%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Equasens Société anonyme Net Profit
Year Net Profit Growth
2004 5.011.000
2005 5.677.000 11.73%
2006 7.304.000 22.28%
2007 -8.554.000 185.39%
2008 9.104.000 193.96%
2009 9.609.000 5.26%
2010 11.040.000 12.96%
2011 11.754.000 6.07%
2012 13.516.000 13.04%
2013 15.825.000 14.59%
2014 17.011.000 6.97%
2015 18.792.000 9.48%
2016 20.567.000 8.63%
2017 23.135.000 11.1%
2018 25.432.000 9.03%
2019 28.403.000 10.46%
2020 30.714.000 7.52%
2021 39.119.000 21.49%
2022 39.464 -99025.79%
2022 46.376.000 99.91%
2023 100.264.000 53.75%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Equasens Société anonyme Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2004 0
2005 0 0%
2006 0 0%
2007 -1 0%
2008 1 0%
2009 1 0%
2010 1 0%
2011 1 0%
2012 1 0%
2013 1 100%
2014 1 0%
2015 1 0%
2016 1 0%
2017 2 0%
2018 2 0%
2019 2 0%
2020 2 50%
2021 3 0%
2022 3 0%
2022 3 33.33%
2023 7 50%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Equasens Société anonyme Free Cashflow
Year Free Cashflow Growth
2004 -595.000
2005 8.523.000 106.98%
2006 1.067.000 -698.78%
2007 6.159.000 82.68%
2010 10.372.000 40.62%
2011 12.322.000 15.83%
2012 15.529.000 20.65%
2013 11.341.000 -36.93%
2014 15.903.999 28.69%
2015 18.462.000 13.86%
2016 16.583.000 -11.33%
2017 19.482.000 14.88%
2018 17.669.000 -10.26%
2019 23.657.000 25.31%
2020 27.534.000 14.08%
2021 37.094.000 25.77%
2022 46.751.000 20.66%
2022 17.250 -270920.29%
2023 -3.571.500 100.48%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Equasens Société anonyme Operating Cashflow
Year Operating Cashflow Growth
2004 8.190.000
2005 10.541.000 22.3%
2006 5.464.000 -92.92%
2007 8.836.000 38.16%
2010 12.345.000 28.42%
2011 14.010.000 11.88%
2012 18.053.000 22.4%
2013 12.290.000 -46.89%
2014 16.687.999 26.35%
2015 19.961.000 16.4%
2016 22.601.000 11.68%
2017 27.186.000 16.87%
2018 28.741.000 5.41%
2019 40.665.000 29.32%
2020 47.208.000 13.86%
2021 47.516.000 0.65%
2022 56.977.000 16.6%
2022 19.495 -292179.68%
2023 2.526.500 99.23%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Equasens Société anonyme Capital Expenditure
Year Capital Expenditure Growth
2004 8.785.000
2005 2.018.000 -335.33%
2006 4.397.000 54.11%
2007 2.677.000 -64.25%
2010 1.973.000 -35.68%
2011 1.688.000 -16.88%
2012 2.524.000 33.12%
2013 949.000 -165.96%
2014 784.000 -21.05%
2015 1.499.000 47.7%
2016 6.018.000 75.09%
2017 7.704.000 21.88%
2018 11.072.000 30.42%
2019 17.008.000 34.9%
2020 19.674.000 13.55%
2021 10.422.000 -88.77%
2022 10.226.000 -1.92%
2022 2.245 -455604.1%
2023 6.098.000 99.96%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Equasens Société anonyme Equity
Year Equity Growth
2004 24.889.000
2005 28.037.000 11.23%
2006 29.599.000 5.28%
2007 33.781.000 12.38%
2008 38.614.000 12.52%
2009 44.244.000 12.72%
2010 51.044.000 13.32%
2011 58.509.000 12.76%
2012 66.922.000 12.57%
2013 76.071.000 12.03%
2014 81.695.000 6.88%
2015 91.556.000 10.77%
2016 103.652.000 11.67%
2017 104.921.999 1.21%
2018 117.051.000 10.36%
2019 131.912.000 11.27%
2020 148.953.000 11.44%
2021 165.235.000 9.85%
2022 196.797.000 16.04%
2022 22.767 -864295.84%
2023 227.626.000 99.99%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Equasens Société anonyme Assets
Year Assets Growth
2004 51.151.000
2005 55.664.000 8.11%
2006 66.752.000 16.61%
2007 70.016.000 4.66%
2008 78.559.000 10.87%
2009 80.234.000 2.09%
2010 84.937.000 5.54%
2011 90.865.000 6.52%
2012 101.905.000 10.83%
2013 109.406.000 6.86%
2014 113.552.000 3.65%
2015 123.981.000 8.41%
2016 150.697.000 17.73%
2017 178.161.000 15.42%
2018 223.808.000 20.4%
2019 258.100.000 13.29%
2020 295.777.000 12.74%
2021 329.950.000 10.36%
2022 350.812.000 5.95%
2022 0 0%
2023 394.045.000 100%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Equasens Société anonyme Liabilities
Year Liabilities Growth
2004 26.262.000
2005 27.627.000 4.94%
2006 37.153.000 25.64%
2007 36.235.000 -2.53%
2008 39.945.000 9.29%
2009 35.990.000 -10.99%
2010 33.893.000 -6.19%
2011 32.356.000 -4.75%
2012 34.983.000 7.51%
2013 33.335.000 -4.94%
2014 31.857.000 -4.64%
2015 32.424.999 1.75%
2016 47.045.000 31.08%
2017 73.239.000 35.77%
2018 106.757.000 31.4%
2019 126.188.000 15.4%
2020 146.824.000 14.05%
2021 164.715.000 10.86%
2022 154.015.000 -6.95%
2022 176.365 -87227.42%
2023 166.419.000 99.89%

Equasens Société anonyme Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
14.47
Net Income per Share
3.1
Price to Earning Ratio
16.98x
Price To Sales Ratio
3.6x
POCF Ratio
13.4
PFCF Ratio
19.18
Price to Book Ratio
3.64
EV to Sales
3.83
EV Over EBITDA
13.27
EV to Operating CashFlow
14.11
EV to FreeCashFlow
20.41
Earnings Yield
0.06
FreeCashFlow Yield
0.05
Market Cap
0,79 Bil.
Enterprise Value
0,84 Bil.
Graham Number
31.71
Graham NetNet
-3.95

Income Statement Metrics

Net Income per Share
3.1
Income Quality
1.27
ROE
0.22
Return On Assets
0.12
Return On Capital Employed
0.19
Net Income per EBT
0.82
EBT Per Ebit
1.04
Ebit per Revenue
0.25
Effective Tax Rate
0.17

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0.02
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.26
Operating Profit Margin
0.25
Pretax Profit Margin
0.26
Net Profit Margin
0.21

Dividends

Dividend Yield
0.02
Dividend Yield %
2.38
Payout Ratio
0.37
Dividend Per Share
1.25

Operating Metrics

Operating Cashflow per Share
3.93
Free CashFlow per Share
2.71
Capex to Operating CashFlow
0.31
Capex to Revenue
0.08
Capex to Depreciation
1.82
Return on Invested Capital
0.16
Return on Tangible Assets
0.18
Days Sales Outstanding
103
Days Payables Outstanding
37.6
Days of Inventory on Hand
24.1
Receivables Turnover
3.54
Payables Turnover
9.71
Inventory Turnover
15.15
Capex per Share
1.21

Balance Sheet

Cash per Share
3,60
Book Value per Share
14,98
Tangible Book Value per Share
6.41
Shareholders Equity per Share
14.43
Interest Debt per Share
4.1
Debt to Equity
0.28
Debt to Assets
0.16
Net Debt to EBITDA
0.8
Current Ratio
1.22
Tangible Asset Value
0,10 Bil.
Net Current Asset Value
-0,03 Bil.
Invested Capital
187292000
Working Capital
0,02 Bil.
Intangibles to Total Assets
0.33
Average Receivables
0,06 Bil.
Average Payables
0,02 Bil.
Average Inventory
10314000
Debt to Market Cap
0.08

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Equasens Société anonyme Dividends
Year Dividends Growth
2014 13
2015 15 14.29%
2016 1 0%
2017 1 0%
2022 1 100%
2023 1 0%
2024 1 0%

Equasens Société anonyme Profile

About Equasens Société anonyme

Equasens Société anonyme provides various IT solutions for the healthcare sector in Europe. It offers LGPI global services and OffiCentral solutions for managing pharmacies and their networks; OffiMSS, OffiSecure, OffiProtect, OffiPass, OffiSeen, OffiCash, Offizzy, and OffiLocker solutions for pharmacists' business processes; and solutions for energizing the customer relationship with pharmacists comprising OffiTag, OffiTouch, OffiMédia, OffiConnect, automation systems, and customer loyalty programs. The company also provides My Pilot, an analytics and management tool; OffiLearning, an e-learning tool; and solutions for patient support and advice, such as compliance monitoring software, Multimeds, Automeds, and OffiTéléconsult, as well as pharmaceutical record and shared medical record services. In addition, it offers a ULTIMATE, a system combining optimized pharmacy management and improved patient support; FARMACLICK, a protocol for communications between pharmacies and wholesalers-distributors; DIFARM, a solution for wholesalers-distributors; PHARE, a retail management tool; SOPHIA, a pharmacy management application; OffiMédia POS display; eNephro to enhance the care of chronic renal failure patients; and TPE Pilot, a web-based application that simplifies the management and sharing of patient education programs. Further, the company provides NOVIACARE; CARELIB Domicile; CARELIB EHPAD; KAPELSE solutions; TITAN solutions; ANTHADINE software and MOBISOINS mobile tool; MICROSOINS, an in-home nursing care solution; and LOGICLIC. Additionally, it offers AXIGATE solutions to manage the entire patient care pathway; CHORUS platform; medical telesecretarial services for healthcare professionals; and equipment lease financing solutions. The company was incorporated in 1996 and is based in Villers-les-Nancy, France. Equasens Société anonyme is a subsidiary of Marque Verte Sante.

CEO
Mr. Grégoire De Rotalier
Employee
1.271
Address
5 AllEe de Saint Cloud
Villers-lès-Nancy, 54601

Equasens Société anonyme Executives & BODs

Equasens Société anonyme Executives & BODs
# Name Age
1 Ms. Sabrina Gharbi
Chief Human Resources Officer
70
2 Mr. Denis Supplisson
Chief Executive Officer & Director
70
3 Mr. Thierry Chapusot
Founder & Chairman of the Board
70
4 Ms. Noelle Stoulig
Head of Communications
70
5 Mr. Grégoire De Rotalier
Deputy Chief Executive Officer, Deputy MD, Director of Healthcare, Medical & Social Software Division and Director
70
6 Mr. Damien Valicon
Deputy MD & Head of the Pharmagest Division
70
7 Ms. Frederique Schmidt
Group Chief Administrative & Financial Officer
70
8 Mr. Dominique Goursaud
Head of the Medical Solutions Division
70
9 Mr. Dominique Pautrat
Director
70

Equasens Société anonyme Competitors